fda warning bpc-157 unapproved peptide safety risk panel narrowly backs drug touted by Joe Rogan and other influencers bpc-157 not approved for human

Growth Hormone & IGF Research

The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)

Reconstitution, aliquoting, and storage parameters should follow institutional SOPs and validated protocols for smallmolecule handling

Side effects may still occur and vary by patient 4